Description: Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Home Page: www.contexttherapeutics.com
2001 Market Street
Philadelphia,
PA
19103
United States
Phone:
(267) 225-7416
Officers
| Name | Title |
|---|---|
| Mr. Martin A. Lehr | Co-Founder, President, CEO & Director |
| Ms. Jennifer Minai-Azary | CFO & Treasurer |
| Mr. Alex C. Levit Esq. | Chief Legal Officer & Corporate Secretary |
| Mr. Christopher Beck M.B.A. | Senior Vice President of Operations |
| Dr. Claudio Dansky Ullmann M.D. | Chief Medical Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.3064 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 5 |